论文部分内容阅读
目的:观察甘露聚糖肽联合吡柔比星膀胱灌注预防膀胱癌术后复发的临床疗效和安全性。方法:将78例非肌层浸润性膀胱癌术后患者随机均分为治疗组和对照组,对照组采用吡柔比星30mg膀胱灌注;治疗组采用40mg甘露聚糖肽联合吡柔比星30mg膀胱灌注。两组均每周灌注1次,共8次,后每月灌注1次,共8次。定期复查膀胱镜,观察两组患者的复发率和不良反应。结果:78例患者均获随访。治疗组患者复发率为5.13%,显著低于对照组的20.51%(P<0.05)。治疗组患者类似流感症状的发生率显著高于对照组(P<0.05),而两组间其他不良反应的发生率比较差异无统计学意义(P>0.05)。结论:甘露聚糖肽联合吡柔比星膀胱灌注能有效降低非肌层浸润性膀胱癌术后复发率,改善患者生存质量,且安全性较高,临床使用耐受性良好。
Objective: To observe the clinical efficacy and safety of mannatide combined with pirarubicin in preventing postoperative recurrence of bladder cancer. Methods: Seventy-eight non-muscle invasive bladder cancer patients were randomly divided into treatment group and control group. The control group was treated with pirarubicin 30mg intravesical instillation. The treatment group was treated with 40mg mannan peptide and pirarubicin 30mg Bladder perfusion. Two groups were perfusion once a week, a total of 8 times, after a monthly perfusion, a total of 8 times. Cystoscopy regularly review the two groups of patients relapse rate and adverse reactions. Results: All 78 patients were followed up. The recurrence rate of the treatment group was 5.13%, which was significantly lower than that of the control group (20.51%, P <0.05). The incidence of flu-like symptoms in the treatment group was significantly higher than that in the control group (P <0.05). There was no significant difference in the incidence of other adverse reactions between the two groups (P> 0.05). Conclusion: Mannatide combined with pirarubicin can reduce the recurrence rate of non-muscle invasive bladder cancer and improve the quality of life of patients with non-muscle invasive bladder cancer, and it is safe and well tolerated in clinic.